sur Relief Therapeutics Holding SA (ETR:RLF)
MindMaze Therapeutics Presents 2026 Half-Year Results
MindMaze Therapeutics Holding SA released its 2026 half-year report on August 27, detailing key advancements and financial outcomes. The Geneva-based company, known for its precision neurotherapeutics, reported H1 revenue of CHF 0.5 million and a net loss of CHF 6.9 million.
The company expanded its U.S. reach by building its commercial organization and partnering with Vibra Healthcare. Real-world evidence from a multi-site program with Vibra demonstrated improved patient outcomes through intensive neurorehabilitation. In Europe, MindMaze advanced its reimbursement strategy and supported a University of Pittsburgh study exploring spinal cord stimulation for stroke recovery.
Additionally, the company simplified its organization by disposing of non-neurology operations and received CHF 4.0 million in equity financing. CEO Zach Henderson emphasized the focus on accelerating commercial adoption and enhancing strategic partnerships.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Relief Therapeutics Holding SA